SPRB Projected Dividend Yield
Spruce Biosciences Inc ( NASDAQ : SPRB )Spruce Biosciences, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing therapies for rare endocrine disorders with significant unmet medical needs. Co. is initially developing its wholly owned product candidate, Tildacerfont, as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (CAH). It is also developing Tildacerfont for females suffering from polycystic ovary syndrome (PCOS). It has initiated CAHmelia-203, a placebo-controlled, double-blind Phase IIb clinical trial in adult patients with classic CAH with elevated levels of androstenedione (A4) at baseline. 21 YEAR PERFORMANCE RESULTS |
SPRB Dividend History Detail SPRB Dividend News SPRB Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |